...and gastritis. Data were presented at the European Crohn’s and Colitis Organization meeting in Amsterdam. Enceladus Pharmaceuticals B.V....

...Galapagos said on a conference call that it sent notice to Enceladus that it is terminating...
...a decision on the future of the Phase II trial (see BioCentury, April 21, 2008). Enceladus Pharmaceuticals B.V....

...Galapagos did not comment on the status of the partnership. Galapagos also said it notified Enceladus Pharmaceuticals B.V....

...The company licensed exclusive, worldwide rights to develop and market Nanocort from Enceladus last year. Enceladus Pharmaceuticals B.V....

...meeting in San Francisco. Galapagos has exclusive, worldwide rights to develop and market Nanocort from Enceladus Pharmaceuticals B.V....

...Ph I/II trials in 1H09 to treat multiple sclerosis (MS) and inflammatory bowel disease (IBD). Enceladus...
...an undisclosed upfront payment and is eligible for a minority share of future Nanocort revenue. Enceladus Pharmaceuticals B.V....